Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 29;12:643501. doi: 10.3389/fmicb.2021.643501

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Chotirat, Nekkab, Kumpitak, Hietanen, White, Kiattibutr, Sa-angchai, Brewster, Schoffer, Takashima, Tsuboi, Harbers, Chitnis, Healer, Tham, Nguitragool, Mueller, Sattabongkot and Longley.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Population-level seropositivity and immunogenicity of the IgG response against 23 P. vivax proteins. IgG levels were measured in 1,873–4,255 individuals from a 2012 Thai cross-sectional survey. (A) The percentage of individuals exceeding equivalent of 1/100 of the PNG pool was calculated using RAU values for each protein. The percentage of individuals seropositive was calculated by comparing to seropositivity cut-offs, defined as the mean + 2× the standard deviation of the negative control samples (n = 274). (B) Population-level seropositivity rates (n = 1,873–4,255) compared to seropositivity rates in individuals with current P. vivax infections (n = 76–144).